Pharma Focus Asia

Sun Pharma Acquires Disperzyme® And Phlogam® Brands

Tuesday, January 31, 2023

Sun Pharmaceutical announced that it has acquired three brands viz. Disperzyme® (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) and Phlogam® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care (“Aksigen”). All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.

Disperzyme® and Phlogam® are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (“TBR”) to complete a clinical study in India and to get DCGI approval.

Disperzyme® and Phlogam®, administered orally, offers systemic enzyme-flavonoid therapy. Disperzyme® and Phlogam® provides the clinicians an evidence-based management solution for inflammation and pain management after minor surgery and dental procedures.

The addition of Disperzyme® and Phlogam® further strengthens anti-inflammatory portfolio. This systemic enzyme therapy combination controls oedema and it speeds-up the healing process. In a comparative clinical trial in India, these brands provides significantly better control and resolution of post-operative pain and inflammation.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024